Q-omics provides the consensus-scored IL6R profile across patient tissues and cancer cell-line models. IL6R expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IL6R is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, IL6R RNA expression shows 19,424 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where IL6R shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL6R — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL6R survival associations across molecular data types. IL6R RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL6R RNA expression–survival associations across cancer types. High IL6R expression shows unfavorable associations in LGG and LAML, but favorable associations in KIRC, MESO, PAAD and SARC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IL6R RNA expression.
This table summarizes IL6R tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for IL6R. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL6R shows lower tumor expression in COAD, LUAD, BLCA and LUSC and higher tumor expression in KIRC and HNSC. The COAD box plot shows higher IL6R RNA expression in normal versus tumor tissue (log2 FC = −2.652, t-test p < 0.001).
This table shows molecular features associated with IL6R in patient tissues and cancer cell lines. In patient samples, IL6R shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, IL6R RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
